Barrow, Hanley, Mewhinney & Strauss
AMPH icon

Barrow, Hanley, Mewhinney & Strauss’s Amphastar Pharmaceuticals AMPH Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$580 – 320
2025
Q1 		$580 Buy
+20
New +$639 ﹤0.01% 303

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's AMPH Position: Q2 2025 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2025, closing a stake of 20 shares — an estimated $580 sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in AMPH in Q1 2025 and held it in 1 quarter. The position peaked at $580 in Q1 2025. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2025.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining Amphastar Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 20 Amphastar Pharmaceuticals shares in Q2 2025, an estimated $580.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Amphastar Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Barrow, Hanley, Mewhinney & Strauss's Amphastar Pharmaceuticals position peaked at $580 in Q1 2025.
  • 245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2025.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2025, filed 12 Aug 2025.